leadf
logo-loader
viewSynairgen PLC

Synairgen phase III trial of potentially breakthrough coronavirus treatment now underway

“We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right support, our drug could rapidly assist with the global crisis," said chief executive, Richard Marsden

Synairgen PLC -

Synairgen PLC (LON:SNG) has said the first patient has been dosed with its inhaled formulation of interferon beta-1a as part of its global phase III trial in people hospitalised coronavirus (COVID-19).

The respiratory drug discovery and development company said dosing with SNG001 had so far only taken place in the UK with work expected to get underway in the US and EU shortly.

In all, the randomised placebo-controlled study will be conducted in around 20 countries, enrolling 610 COVID-19 patients who require supplemental oxygen.

After reporting the results for the primary and key secondary goals, enrolled patients will continue to be monitored for long-Covid symptoms.

In the UK, Synairgen’s clinical assessment is deemed an urgent public health study, while it also has US Food & Drug Administration fast-track status.

The company is seeking “further equivalent prioritisations and support” from governments in participating countries, investors were told.

In s statement, Synairgen chief executive, Richard Marsden, said: "We need treatments as well as vaccines to fight highly pathogenic viruses such as SARS-CoV-2. Development of treatments like ours will remain necessary in cases where vaccines are not effective, for those who do not get vaccinated, and in case the virus mutates to the point where vaccines become less effective.

“We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right support, our drug could rapidly assist with the global crisis."

Quick facts: Synairgen PLC

Price: 174 GBX

AIM:SNG
Market: AIM
Market Cap: £347.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read